Targeting EGFR in bladder cancer.

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Epidermal growth factor receptor (EGFR) alterations, including mutations and overexpression, are implicated in various solid tumors.
• EGFR mutations and the variant EGFRvIII are linked to patient response to targeted therapies like gefitinib.
• Urothelial carcinoma's potential reliance on EGFR alterations necessitates investigation.

Purpose of the Study:

• To investigate the presence and significance of EGFR kinase domain mutations and EGFRvIII expression in urothelial carcinoma.
• To determine if these EGFR alterations contribute to the malignant phenotype of bladder cancer.
• To inform therapeutic strategies involving tyrosine kinase inhibitors for urothelial carcinoma.

Main Methods:

• Automated sequencing of the EGFR kinase domain (exons 18-21) in 11 bladder cancer cell lines and 75 patient tumors.
• Immunohistochemistry to detect EGFRvIII expression in urothelial carcinoma tissue microarrays.
• Validation of EGFRvIII detection using reverse transcription PCR, real-time PCR, and western blot analysis.

Main Results:

• No EGFR kinase domain mutations were detected in any of the tested bladder cancer cell lines or patient tumors.
• Initial immunohistochemistry suggested EGFRvIII expression in nearly half of patient samples.
• Subsequent validation by RT-PCR, real-time PCR, and western blot confirmed the absence of EGFRvIII in all tested samples.

Conclusions:

• Mutations within the EGFR tyrosine kinase domain are rare in bladder cancer.
• EGFRvIII expression is also not detected in urothelial carcinoma, despite initial immunohistochemistry findings.
• These EGFR alterations do not appear to be significant drivers of bladder cancer, influencing the choice of targeted therapies.